Hernando Knobel

Hernando Knobel publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Hernando Knobel sits on this spectrum.

Hernando Knobel D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Hernando Knobel sits on this spectrum.

Best Publications

• Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study.

  Hernando Knobel;Jordi Alonso;José L Casado;Julio Collazos

  654
  Citations

• Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients.

  Unknown

  606
  Citations

• Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain.

  J. Berenguer;P. Ryan;J. Rodríguez-Baño;I. Jarrín

  415
  Citations

• Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.

  Esteban Martínez;Juan A. Arnaiz;Daniel Podzamczer;David Dalmau

  388
  Citations

• Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study

  Luisa Sorlí;Sonia Luque;Santiago Grau;Núria Berenguer

  256
  Citations

• Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

  Esteban Martinez;María Larrousse;Josep M Llibre;Felix Gutierrez

  239
  Citations

• Osteopenia in HIV-infected patients: is it the disease or is it the treatment?

  Unknown

  230
  Citations

• Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study.

  Roser Terradas;Santiago Grau;Jordi Blanch;Marta Riu

  200
  Citations

• A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).

  Daniel Podzamczer;Elena Ferrer;Ezequiel Consiglio;José Maria Gatell

  192
  Citations

• Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients.

  Rosario Palacios;Francisco Jiménez-Oñate;Manuela Aguilar;Maria José Galindo

  190
  Citations

• Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

  José R Arribas;Pierre-Marie Girard;Roland Landman;Judit Pich

  189
  Citations

• Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial.

  Judit Villar-García;Juan J. Hernández;Robert Güerri-Fernández;Alicia González

  163
  Citations

• HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: A population-based cohort study

  Robert Güerri-Fernandez;Peter Vestergaard;Cristina Carbonell;Hernando Knobel

  148
  Citations

• Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

  Jose R Arribas;Rafael Delgado;Alberto Arranz;Rosa Muñoz

  147
  Citations

• Hypertension in HIV-Infected Patients: Prevalence and Related Factors

  Unknown

  129
  Citations

• Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.

  Federico Pulido;Esteban Ribera;María Lagarde;Ignacio Pérez-Valero

  126
  Citations

• Adherence and Effectiveness of Highly Active Antiretroviral Therapy

  Unknown

  126
  Citations

• Subclinical Carotid Atherosclerosis in HIV-Infected Patients Role of Combination Antiretroviral Therapy

  Unknown

  126
  Citations

• Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

  Chloe Orkin;Jean-Michel Molina;Eugenia Negredo;José R Arribas

  123
  Citations

• Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.

  Unknown

  122
  Citations